Table 1

Participant baseline characteristics, overall and anti-TNF utilisation status

Full sample (n=8502)anti-TNF non-users (n=8186)New episode of anti-TNF users (n=121)*
Age mean (SD)76 (8)76 (8)73 (6)
 Rocky Mountains23932343<11†
Medicaid coverage191523188523<11†
Polypharmacy (≥5 drugs)4920624719627260
Charlson Index Mean (SD)1 (2)1 (2)1 (2)
Gastroenterologist visit4392524158517663
>1 endoscopy1183141141142017
IBD surgery21131992<11†
Hospitalisations mean (SD)1 (1)1 (1)1 (1)
  • *New anti-TNF utilisers initiated therapy after the completion of the baseline period; bivariate analyses is the comparison of new episodes of use to non-use (n=8307); prevalent anti-TNF utilisers were already receiving therapy during the baseline study period (n=195) and were excluded from anti-TNF non-users group (n=8186).

  • †Cell size is too small and requires suppression as part of the data use agreement.

  • ‡Includes Hawaii, Alaska and Puerto Rico.

  • IBD, inflammatory bowel disease; TNF, tumour necrosis factor.